Management remains focused on achieving leasing and SNO pipeline targets, with Hsieh stating, "Our initial goal on new deals was 50% progress by mid-2025 and 70% by year-end 2025. Hitting the 70% goal ...

Precision medicine is reshaping the landscape of clinical development, offering more advanced strategies to align therapies with individual biological variability. Recent research shows that drug ...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES Brisbane, Australia–(Newsfile Corp. ...

Highlights Near-Term Development at Maria Norte, District-Scale Exploration Upside in Peru, and Strategic Optionality from Canada’s Ring of Fire Critical Minerals Asset ...

If there’s one word that best describes the current climate around U.S.-Mexico trade, it’s uncertainty. Ever since former President Trump announced plans to impose a 25% tariff on Mexican goods, ...

Since 2009, I’ve had the privilege of working with organizations worldwide to leverage the power of diversity, equity and inclusion (DEI) to enhance their businesses. One of the most critical advances ...

DeFi Development Corp. projects Solana growth, aiming for 1.0 SPS by December 2028, and recently bought 10,758 SOL. DeFi Development Corp. (Nasdaq: DFDV), the first publicly traded company in the U.S.

Bio-Path Holdings, Inc. has provided an update on its clinical developments during a recent conference call. The company is focused on using its DNAbilize® liposomal delivery technology to develop ...